Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
July 01, 2024 07:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
May 13, 2024 08:15 ET
|
Benitec Biopharma Inc.
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April- -The Second OPMD...
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
May 01, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
April 18, 2024 07:30 ET
|
Benitec Biopharma Inc.
-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- - BB-301 facilitated improvements...
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
April 18, 2024 07:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
April 09, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
February 13, 2024 08:00 ET
|
Benitec Biopharma Inc.
-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit- ...
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
November 30, 2023 07:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
November 17, 2023 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
November 13, 2023 08:00 ET
|
Benitec Biopharma Inc.
Benitec Biopharma, a genetic medicines company, releases updates on OPMD program and other corporate and financial updates.